What is the Destiny Breast 11 trial for adult females with HER2-positive metastatic breast cancer who have received prior treatments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: January 18, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

What is the role of the Destiny Breast 05 trial in treating a patient with HER2-positive metastatic breast cancer who has previously received trastuzumab (Herceptin) and a taxane?

What is the role of trastuzumab deruxtecan (trastuzumab deruxtecan) in the treatment of patients with HER2-positive metastatic breast cancer, particularly those who have received prior treatments including trastuzumab and pertuzumab?

What is the recommended number of cycles of Emhertu (trastuzumab deruxtecan) for a patient with metastatic invasive ductal carcinoma (IDC) being considered for third-line treatment?

What is the recommended treatment protocol for patients with HER2-positive breast cancer using Fam-trastuzumab deruxtecan-nxki (Trastuzumab deruxtecan)?

What is the evidence for trastuzumab deruxtecan (trastuzumab deruxtecan) or T-DM1 (ado-trastuzumab emtansine) after progression on lapatinib (lapatinib) for metastatic (mets) breast cancer that is HER2-positive?

What is the best course of treatment for an adult patient with a decreased total white blood cell (WBC) count and persistently elevated C-reactive protein (CRP) levels, indicating a possible infection or inflammatory condition?

What is the best treatment approach for a patient with an electrical injury and a wound culture positive for Enterobacter (E.) cloacae and Pantoea agglomerans?

What could be the contributing factors in the IVF (In Vitro Fertilization) lab for embryos from three patients to develop into blastocysts by day 7, rather than the expected day 5, after being cultured from day 3?

What is the best course of treatment for a patient with uterine didelphys, unilateral hematocolpos and hematometra, and unilateral renal (kidney) agenesis?

What is the next step for an adult patient with a history of migraines who did not respond to sumatriptan (Imigran) for an acute migraine?

When to suspend and reinstate anticoagulants in patients with impaired renal function requiring thromboprophylactic and therapeutic doses?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.